The Retinoblastoma drugs in development market research report provides comprehensive information on the therapeutics under development for Retinoblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Retinoblastoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Retinoblastoma by 13 companies/universities/institutes. The top development phase for Retinoblastoma is preclinical with 11 drugs in that stage. The Retinoblastoma pipeline has 15 drugs in development by companies and one by universities/ institutes. Some of the companies in the Retinoblastoma pipeline products market are: Canget BioTekpharma, Targeted Therapy Technologies and Oxular.
The key targets in the Retinoblastoma pipeline products market include E3 Ubiquitin Protein Ligase Mdm2, DNA Topoisomerase I, and Cyclin Dependent Kinase 6.
The key mechanisms of action in the Retinoblastoma pipeline product include DNA Topoisomerase I Inhibitor with two drugs in Phase I. The Retinoblastoma pipeline products include six routes of administration with the top ROA being Intravitreal and five key molecule types in the Retinoblastoma pipeline products market including Small Molecule, and Oncolytic Virus.
Retinoblastoma overview
Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris, and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy, and surgery.
For a complete picture of Retinoblastoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
